JIM CRAMERMore Positives Than Negatives: Cramer's 'Mad Money' RecapBy Scott RuttOct 21, 2019 10:45 PM EDT
PRESS RELEASESSeattle Genetics To Present At The Cowen 40th Annual Healthcare ConferenceBy Business WireFeb 26, 2020 8:00 AM EST
PRESS RELEASESSeattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For PADCEV™ (enfortumab Vedotin-ejfv) In Combination With Pembrolizumab In First-Line Advanced Bladder CancerBy Business WireFeb 19, 2020 8:12 AM EST
PRESS RELEASESSeattle Genetics Announces FDA Filing Acceptance For Priority Review Of Tucatinib New Drug Application (NDA) For Patients With Locally Advanced Or Metastatic HER2-Positive Breast CancerBy Business WireFeb 13, 2020 8:00 AM EST
PRESS RELEASESEMA Validates Seattle Genetics' Marketing Authorization Application For Tucatinib For Patients With Locally Advanced Or Metastatic HER2-Positive Breast CancerBy Business WireJan 31, 2020 8:00 AM EST
PRESS RELEASESSeattle Genetics To Host Conference Call And Webcast Discussion Of Fourth Quarter And Full Year 2019 Financial Results On February 6, 2020By Business WireJan 21, 2020 8:30 AM EST
PRESS RELEASESSeattle Genetics Achieves Milestone Following European Commission Approval Of Roche's Polivy® (Polatuzumab Vedotin)By Business WireJan 21, 2020 8:00 AM EST
JIM CRAMERMore Positives Than Negatives: Cramer's 'Mad Money' RecapBy Scott RuttOct 21, 2019 10:45 PM EDT
JIM CRAMERMerck, Cloudflare, Exelon: 'Mad Money' Lightning RoundBy Scott RuttOct 21, 2019 10:37 PM EDT
MARKETSSeattle Genetics Shares Rise On Positive Results From Breast Cancer Drug TrialBy Brenda BouwOct 21, 2019 11:04 AM EDT
STOCKSSeattle Genetics Climbs on Positive Trial Results for Bladder Cancer TreatmentBy Tony OwusuSep 30, 2019 1:15 PM EDT
STOCKSImmunomedics Stock Drops After Bladder-Cancer-Drug Results DisappointBy Tony OwusuSep 30, 2019 12:33 PM EDT
JIM CRAMERBerkshire Hathaway, Seattle Genetics, Zynerba: 'Mad Money' Lightning RoundBy Scott RuttJul 22, 2019 8:35 PM EDT
MARKETSBiotech Stocks Post Double-Digit Gains in Monday SurgeBy Scott Van VoorhisJan 7, 2019 6:49 PM EST
JIM CRAMERCisco Systems, Herbalife, Under Armour: 'Mad Money' Lightning RoundBy Scott RuttJul 12, 2018 6:33 AM EDT
JIM CRAMERDeere & Co., Analog Devices, Mercadolibre: 'Mad Money' Lightning RoundBy Scott RuttJan 9, 2018 6:34 AM EST
JIM CRAMERGood News Matters in This Market: Cramer's 'Mad Money' RecapBy Scott RuttJan 9, 2018 6:26 AM EST
JIM CRAMERCatch of the Day: Cramer's 'Mad Money' Recap (Wednesday 10/11/17)By Scott RuttOct 12, 2017 6:15 AM EDT
JIM CRAMERWalgreens Boots Alliance, Snap, Teva: 'Mad Money' Lightning RoundBy Scott RuttOct 5, 2017 6:38 AM EDT
STOCKSRigel Jumps on Update on FDA Review of Bleeding Disorder TreatmentBy Armie Margaret LeeOct 2, 2017 9:26 AM EDT
REGULATIONBiotech Leaders Join Corporate Chorus Angry Over Trump's DACA MoveBy Bill MeagherSep 6, 2017 3:20 PM EDT
HEALTHBiotech Movers: Seattle Genetics, Valeant, ImmunoGenBy Armie Margaret LeeJun 26, 2017 9:32 PM EDT
